Thermo Fisher expands into gene therapy in $1.7bn deal
Biotech company Thermo Fisher Scientific has announced plans to acquire Brammer Bio, a viral vector manufacturer for gene and cell therapies, for $1.7 billion.
Questions on Neurim scope remain post-SPC ruling, say lawyers
The Court of Justice of the European Union’s recent refusal to provide further guidance on the full scope of Neurim in a case involving supplementary protection certificates last week has left some big questions unanswered.
UK biotech R&D up 65% since 2016, says report
A “biotech boom” is underway in the UK, according to a new report from UK investment management firm Downing.
Strawberry breeder accuses competitor of patent infringement
A California-based company which breeds berries has filed a patent infringement claim against a competitor.
CJEU puts further brakes on SPCs
The Court of Justice of the European Union yesterday, March 21, handed down a supplementary protection certificate decision referred to it by the English High Court.
Seven new drugs to join $1bn club by 2021, says Clarivate
Seven new drugs are forecasted to achieve annual sales of $1 billion or more by 2023, according to a new report.
WHO to begin working on gene editing research registry
World Health Organization (WHO) experts have called for central registry on human genome editing research is needed, among a committee consensus that it would be irresponsible for any scientist to conduct gene-editing studies in people.
EU court backs medical device company over EUIPO
The EU General Court yesterday, March 20, annulled a European Union Intellectual Property Office (EUIPO) decision and handed a trademark victory to Spain-based Prim.
Allergan and tribe hit back at Mylan claims in SCOTUS brief
Allergan and the Saint Regis Mohawk Tribe have again urged the US Supreme Court to hear their closely-followed litigation on tribal sovereign immunity, following a submission from generic maker Mylan in the case.
SCOTUS to hear pharmaceutical patent dispute
The US Supreme Court will seek the advice of the country’s solicitor general after it agreed to hear an appeal in a dispute over whether a medical treatment is directed towards a natural law.
